AU2008234364B2 - Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery - Google Patents

Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery Download PDF

Info

Publication number
AU2008234364B2
AU2008234364B2 AU2008234364A AU2008234364A AU2008234364B2 AU 2008234364 B2 AU2008234364 B2 AU 2008234364B2 AU 2008234364 A AU2008234364 A AU 2008234364A AU 2008234364 A AU2008234364 A AU 2008234364A AU 2008234364 B2 AU2008234364 B2 AU 2008234364B2
Authority
AU
Australia
Prior art keywords
composition
interferon alpha
treatment
oil
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008234364A
Other languages
English (en)
Other versions
AU2008234364A1 (en
Inventor
John M. Docherty
Marianna Foldvari
Praveen Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altum-Avro Pharma Partnership
Original Assignee
Altum Avro Pharma Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altum Avro Pharma Partnership filed Critical Altum Avro Pharma Partnership
Publication of AU2008234364A1 publication Critical patent/AU2008234364A1/en
Assigned to HELIX BIOPHARMA CORP. reassignment HELIX BIOPHARMA CORP. Request for Assignment Assignors: PHARMADERM LABORATORIES LTD.
Application granted granted Critical
Publication of AU2008234364B2 publication Critical patent/AU2008234364B2/en
Assigned to ALTUM-AVRO PHARMA PARTNERSHIP reassignment ALTUM-AVRO PHARMA PARTNERSHIP Request for Assignment Assignors: HELIX BIOPHARMA CORP.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008234364A 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery Ceased AU2008234364B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90932407P 2007-03-30 2007-03-30
US60/909,324 2007-03-30
PCT/CA2008/000563 WO2008119160A1 (en) 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery

Publications (2)

Publication Number Publication Date
AU2008234364A1 AU2008234364A1 (en) 2008-10-09
AU2008234364B2 true AU2008234364B2 (en) 2013-10-17

Family

ID=39807744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008234364A Ceased AU2008234364B2 (en) 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery

Country Status (18)

Country Link
US (3) US8945529B2 (enExample)
EP (1) EP2134353B1 (enExample)
JP (1) JP5587762B2 (enExample)
KR (1) KR20090130081A (enExample)
AU (1) AU2008234364B2 (enExample)
CA (1) CA2681565C (enExample)
CY (1) CY1118794T1 (enExample)
DK (1) DK2134353T3 (enExample)
ES (1) ES2617063T3 (enExample)
HR (1) HRP20170250T1 (enExample)
HU (1) HUE033256T2 (enExample)
LT (1) LT2134353T (enExample)
MX (1) MX2009010405A (enExample)
PL (1) PL2134353T3 (enExample)
PT (1) PT2134353T (enExample)
SI (1) SI2134353T1 (enExample)
TW (1) TWI440477B (enExample)
WO (1) WO2008119160A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
US8986732B2 (en) * 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
CN111093633A (zh) * 2017-05-26 2020-05-01 奥特姆医药公司 双相大麻素递送
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
JP7423522B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
MX2022003446A (es) * 2019-09-23 2022-07-13 Dds Res Inc Composiciones de vesiculas lipidicas con agentes potenciadores de la penetracion.
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
KR20240035939A (ko) 2021-03-24 2024-03-19 글로 파마, 인크. 피부 색소침착을 감소시키기 위한 펩타이드 및 방법
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023081259A2 (en) * 2021-11-04 2023-05-11 Glo Pharma, Inc. Methods and compositions for cosmetic applications
MA71619A (fr) 2022-07-26 2025-05-30 Modernatx, Inc. Polynucléotides modifiés pour la régulation temporelle de l'expression
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003787A1 (en) * 1993-07-28 1995-02-09 University Of Saskatchewan Biphasic multilamellar lipid vesicles
WO1999011247A1 (en) * 1997-08-29 1999-03-11 Pharmaderm Laboratories, Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1576952A1 (en) * 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003787A1 (en) * 1993-07-28 1995-02-09 University Of Saskatchewan Biphasic multilamellar lipid vesicles
WO1999011247A1 (en) * 1997-08-29 1999-03-11 Pharmaderm Laboratories, Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STELLATO G. SEXUALLY TRANSMITTED DISEASES MAY -JUN 1992, VOL 19, NO 3, PAGES 124-126 *
YLISKOSKI M ET AL, GYNECOLOGIC ONCOLOGY MARCH 1990, VOL 36, NO 3, PAGES 353-357 *

Also Published As

Publication number Publication date
PL2134353T3 (pl) 2017-06-30
EP2134353B1 (en) 2016-11-16
HRP20170250T1 (hr) 2017-04-07
CA2681565C (en) 2016-10-25
JP2010522698A (ja) 2010-07-08
CA2681565A1 (en) 2008-10-09
WO2008119160A1 (en) 2008-10-09
SI2134353T1 (sl) 2017-03-31
PT2134353T (pt) 2017-02-15
US20130216610A1 (en) 2013-08-22
MX2009010405A (es) 2010-02-03
LT2134353T (lt) 2017-03-27
JP5587762B2 (ja) 2014-09-10
US20100196453A1 (en) 2010-08-05
US8945529B2 (en) 2015-02-03
ES2617063T3 (es) 2017-06-15
DK2134353T3 (en) 2017-02-20
AU2008234364A1 (en) 2008-10-09
KR20090130081A (ko) 2009-12-17
US20130224283A1 (en) 2013-08-29
EP2134353A1 (en) 2009-12-23
HUE033256T2 (hu) 2017-11-28
CY1118794T1 (el) 2017-07-12
TW200846030A (en) 2008-12-01
TWI440477B (zh) 2014-06-11
EP2134353A4 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
AU2008234364B2 (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
US5853755A (en) Biphasic multilamellar lipid vesicles
KR0157428B1 (ko) 비 전달용 지질부형제와 그 사용법
JP4755742B2 (ja) 医薬最終処方物におけるナノディスパージョンの使用
EP0711148B1 (en) Biphasic multilamellar lipid vesicles
US20040208921A1 (en) Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
CA2172110A1 (en) Pharmaceutical carriers for nanosuspensions
EP0437577A1 (en) Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
HUP0101026A2 (hu) Parenterálisan alkalmazható, liposzóma alapú diszperziós eritropoietin készítmények
US6656499B1 (en) Composition for transdermal and dermal administration of interferon-α
US20130085146A1 (en) Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
Foldvari et al. Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
US20150044275A1 (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US9011924B2 (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
HK1135913B (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
HK1135913A (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
JPH10316555A (ja) 高分子化合物を含有するリポソーム外用剤
MOURTAS et al. Liposomal gels for vaginal delivery of the microbicide MC-1220: preparation and in vivo vaginal toxicity and pharmacokinetics
CN121731479A (zh) 七叶皂苷钠或其异构体作为渗透促进剂的应用
TW202519194A (zh) 用於疼痛控制之關節內皮質類固醇的微脂體組成物
Li Pulmonary insulin absorption enhancement by bile salts and liposomes

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HELIX BIOPHARMA CORP.

Free format text: FORMER APPLICANT(S): PHARMADERM LABORATORIES LTD.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALTUM-AVRO PHARMA PARTNERSHIP

Free format text: FORMER OWNER(S): HELIX BIOPHARMA CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired